Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity

Journal of Controlled Release

Volumn 160, Issue 3, 2012, Pages 618-629

  Liang, Liang ^a   Lin, Song Wen ^a   Dai, Wenbing ^a   Lu, Jing Kai ^a   Yang, Ting Yuan ^a   Xiang, Yu ^a   Zhang, Yang ^a   Li, Run Tao ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anti tumor effect; Cathepsin B sensitive; Conjugate; Paclitaxel; Pegylated

Indexed keywords

ANTITUMOR EFFECT; CATHEPSIN B-SENSITIVE; CONJUGATE; PACLITAXEL; PEGYLATED;

AMINO ACIDS; CELL CULTURE; ETHANOL; ORGANIC SOLVENTS; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE ACTIVE AGENTS; TOXICITY; TUMORS;

WATER INJECTION;

4 AMINOBENZYLCARBONYL; ALCOHOL; CARBONYL DERIVATIVE; CATHEPSIN B; CITRULLINE; CITRULLINE DIPEPTIDE; CREMOPHOR; MACROGOL; PACLITAXEL; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATHEPSIN B; CELL CYCLE; CELL LINE, TUMOR; CITRULLINE; DIPEPTIDES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; POLYETHYLENE GLYCOLS; TUMOR BURDEN; VALINE;

EID: 84861986282     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.02.020     Document Type: Article

References (44)

1. WorldHealthOrganization, Cancer, http://www.who.int/cancer/enAccessed July, 2010.
2. I. Ojima, Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxoids as warheads, Acc. Chem. Res. 41 (1) (2008) 108-119.
3. M.C. Wani, H.L. Taylo, M.E. Wall, P. Coggon, A.T. Mcphail, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J. Am. Chem. Soc. 93 (1971) 2325-2327.
4. R.D. Dabholkar, R.M. Sawant, D.A. Mongayt, P.V. Devarajan, V.P. Torchilin, Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of Pglycoprotein-mediated efflux, Int. J. Pharm. 315 (2006) 148-157.
5. A. Safavy, K.P. Raisch, M.B. Khazaeli, D.J. Buchsbaum, J.A. Bonner, Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes, J. Med. Chem. 42 (1999) 4919-4924.
6. X.F. Zhang, Y.X. Li, X.S. Chen, X.H. Wang, X.Y. Xu, Q.Z. Liang, J.L. Hu, X.B. Jing, Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate, Biomaterials 26 (2005) 2121-2128.
7. X.D. Guo, J.P.K. Tan, S.H. Kim, L.J. Zhang, Y. Zhang, J.L. Hedrick, Y.Y. Yang, Y. Qian, Computational studies on self-assembled paclitaxel structures: templates for hierarchical block copolymer assemblies and sustained drug release, Biomaterials 30 (2009) 6556-6563.
8. H. Ringsdorf, Structure and properties of pharmacologically active polymers, J. Polym. Sci. Symp. 51 (1975) 135-153.
9. F. Greco, M.J. Vicent, Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines, Adv. Drug Deliv. Rev. 61 (2009) 1203-1213.
10. J.W. Singer, S. Shaffer, B. Baker, A. Bernareggi, S. Stromatt, D. Nienstedt, M. Besman, Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane, Anticancer Drugs 16 (2005) 243-254.
11. T.M. Beer, C. Ryan, J. Alumkal, C.W. Ryan, J. Sun, K.M. Eilers, A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy, Anticancer Drugs 21 (2010) 433-438.
12. C. Li, S. Wallace, Polymer-drug conjugates: recent development in clinical oncology, Adv. Drug Deliv. Rev. 60 (2008) 886-898.
13. J.W. Singer, Paclitaxel poliglumex (XYOTAXTM, CT-2103): a macromolecular taxane, J. Control. Release 109 (2005) 120-126.
14. M.J. Vicent, R. Duncan, Polymer conjugates: nanosized medicines for treating cancer, Trends Biotechnol. 24 (2006) 39-47.
15. J.M. Harris, R.B. Chess, Effect of PEGylation on pharmaceuticals, Nat. Rev. Drug Discov. 2 (2003) 214-221.
16. G. Pasut, F.M. Veronese, PEG conjugates in clinical development or use as anticancer agents: an overview, Adv. Drug Deliv. Rev. 61 (2009) 1177-1188.
17. R.B. Greenwald, C.D. Conover, Y.H. Choe, Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review, Crit. Rev. Ther. Drug Carrier Syst. 17 (2000) 101-161.
18. A. Nori, J. Kopecek, Intracellular targeting of polymer-bound drugs for cancer chemotherapy, Adv. Drug Deliv. Rev. 57 (2005) 609-636.
19. D. Schmaljohann, Thermo- and pH-responsive polymers in drug delivery, Adv. Drug Deliv. Rev. 58 (2006) 1655-1670.
20. G. Saito, J.A. Swanson, K.D. Lee, Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities, Adv. Drug Deliv. Rev. 55 (2003) 199-215.
21. D. Filpula, H. Zhao, Releasable PEGylation of proteins with customized linkers, Adv. Drug Deliv. Rev. 60 (2008) 29-49.
22. F.M. Veronese, O. Schiavon, G. Pasut, R. Mendichi, L. Andersson, A. Tsirk, J. Ford, G. Wu, S. Kneller, J. Davies, R. Duncan, PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity, Bioconjug. Chem. 16 (2005) 775-784.
23. C.D. Conover, R.B.Greenwald,A. Pendri,K. Shum, Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs, Anticancer Drug Des. 14 (6) (1999) 499-506 (8).
24. J.S. Mort, D.J. Buttle, Cathepsin B, Int. J. Biochem. Cell Biol. 29 (1997) 715-720.
25. O. Vasiljeva, B. Turk, Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion, Biochimie 90 (2008) 380-386.
26. H. Nishikawa, Y. Ozaki, T. Nakanishi, K. Blomgren, T. Tada, A. Arakawa, K. Suzumori, The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer, Gynecol. Oncol. 92 (2004) 881-886.
27. M. Devetzi, A. Scorilas, E. Tsiambas, M. Sameni, S. Fotiou, B.F. Sloane, M. Talieri, Cathepsin B protein levels in endometrial cancer: potential value as a tumor biomarker, Gynecol. Oncol. 112 (2009) 531-536.
28. M.M. Mohamed, B.F. Sloane, Cysteine cathepsins: multifunctional enzymes in cancer, Nat. Rev. Cancer 6 (2006) 764-775.
29. G.M. Dubowchik, R.A. Firestone, L. Padilla, D. Willner, S.J. Hofstead, K. Mosure, J.O. Knipe, S.J. Lasch, P.A. Trail, Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity, Bioconjug. Chem. 13 (2002) 855-869.
30. S.O. Doronina, B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Gerveny, D.F. Chace, R.L. DeBlanc, R.P. Gearing, T.D. Bovee, C.B. Siegall, J.A. Francisco, A.F. Wahl, D.L. Meyer, P.D. Senter, Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nat. Biotechnol. 21 (7) (2003) 778-784.
31. S.C. Kim, J. Yu, J.W. Lee, E.S. Park, S.C. Chi, Sensitive HPLC method for quantitation of paclitaxel (Genexol®) in biological samples with application to preclinical pharmacokinetics and biodistribution, J. Pharm. Biomed. 39 (2005) 170-176.
32. V. Vichai, K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening, Nat. Protoc. 1 (3) (2006) 1112-1116.
33. Z. Wang, P.C. Ho, A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities, Biomaterials 31 (2010) 7115-7123.
34. J.D. Liang, J. Liu, P. McClelland, M. Bergeron, Cellular localization of BM88 mRNA in paraffin-embedded rat brain sections by combined immunohistochemistry and non-radioactive in situ hybridization, Brain Res. Protoc. 7 (2001) 121-130.
35. J.J. Manfredi, S.B. Horwitz, Taxol: an antimitotic agent with a new mechanism of action, Pharmacol. Ther. 25 (1) (1984) 83-125.
36. J.F. Diaz, J.M. Andreu, Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition, Biochemistry 32 (11) (1993) 2747-2755.
37. W.Y. Seow, J.M. Xue, Y.Y. Yang, Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles, Biomaterials 28 (2007) 1730-1740.
38. R.T. Dorr, Pharmacology and toxicology of Cremophor EL diluent, Ann. Pharmacother. 28 (1994) S11-S14.
39. H.S. Yoo, T.G. Park, Folate-receptor-targeted delivery of doxorubicin nanoaggregates stabilized by doxorubicin-PEG-folate conjugate, J. Control. Release 100 (2004) 247-256.
40. R. Erez, E. Segal, K. Miller, R. Satchi-Fainaro, D. Shabat, Enhanced cytoxicity of a polymer-drug conjugate with triple payload of paclitaxel, Bioorg. Med. Chem. 17 (2009) 4327-4335.
41. K.A. Ajaj, M.L. Biniossek, F. Kratz, Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs, Bioconjug. Chem. 20 (2009) 390-396.
42. S.E. Pratt, M.N. Pollak, Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media, Cancer Res. 53 (1993) 5193-5198.
43. C.K. Osborne, K. Hobbs, J.M. Trent, Biological differences among MCF-7 human breast cancer cell lines from different laboratories, Breast Cancer Res. Treat. 9 (2) (1987) 111-121.
44. S. Ning, K. Trisler, D.M. Brown, N.Y. Yu, S. Kanekal, M.J. Lundsten, S.J. Knox, Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel, Radiol. Oncol. 39 (1996) 179-189.